NeoGenomics’ RaDaR ST MRD assay received expanded Medicare coverage under CMS’s MolDX program for immunotherapy response monitoring in late-stage solid tumors.
Coverage adds a third reimbursed indication for RaDaR ST, alongside head and neck squamous cell carcinoma and a subset of HR+ HER2-negative breast cancer.
The decision broadens reimbursement access for longitudinal ctDNA testing during systemic therapy, a potential driver of test utilization in advanced cancer care.
NEO•
